MSD preparing to take on Beyfortus with RSV antibody
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting
Newsletters and Deep Dive digital magazine
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting
Jörg Möller's sojourn as chief executive of BenevolentAI has come to an abrupt end after just nine months, as the company names co-founder Ken Mulvany as its executive chairman.
Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea
Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug for Alzheimer's and Parkinson's disease.
Researchers have created a map of human skin that uses genomics and other technologies to understand how skin forms and the mechanisms behind skin disorders.
Editor's Picks
Newsletters and Deep Dive
digital magazine